ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with ...

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of a health economics abstract from the BRAVO study at the Society of Urologic Oncology 2025 Annual Meeting (SUO) ...

Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort ...

Photocure ASA ( ($PHCUF) ) has provided an announcement. Photocure ASA presented findings from the BRAVO study at the Society of Urologic Oncology ...

Gene one of nine companies awarded CDRP per yearProgram aims to support CMC development of products with expedited clinical development timeframes and provide patients with earlier access to these ...

Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable ...

The FDA is investigating a safety signal from Takeda’s rare disease med Adzynma. Otsuka won a first-in-class FDA approval to ...

Detailed price information for Cg Oncology Inc (CGON-Q) from The Globe and Mail including charting and trades.

The health secretary says he will balance the arguments for and against mass testing ahead of a final decision due in March.

New approaches hurdle biological barriers to attack recalcitrant targets to tackle difficult-to-treat and recurrent cancers.

Detailed price information for Cg Oncology Inc (CGON-Q) from The Globe and Mail including charting and trades.

Johnson & Johnson’s JNJ stock has risen 16.7% in the past three months. A lot of this price increase is due to strong third-quarter 2025 results, where in both the top and bottom lines exceeded ...